Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 2.27 |
Open | 2.29 |
1-Year Change | -68.28% |
Day's Range | 2.25 - 2.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 26, 2024 | 2.30 | 0.04 | 1.77% | 2.26 | 2.38 | 2.25 |
Apr 25, 2024 | 2.27 | -0.12 | -5.02% | 2.39 | 2.40 | 2.18 |
Apr 24, 2024 | 2.48 | -0.01 | -0.40% | 2.49 | 2.53 | 2.31 |
Apr 23, 2024 | 2.55 | 0.05 | 2.00% | 2.50 | 2.59 | 2.47 |
Apr 22, 2024 | 2.50 | 0.05 | 2.04% | 2.45 | 2.55 | 2.40 |
Apr 19, 2024 | 2.41 | 0.02 | 0.84% | 2.39 | 2.45 | 2.33 |
Apr 18, 2024 | 2.41 | -0.09 | -3.60% | 2.50 | 2.52 | 2.41 |
Apr 17, 2024 | 2.54 | -0.13 | -4.87% | 2.67 | 2.67 | 2.51 |
Apr 16, 2024 | 2.63 | 0.06 | 2.33% | 2.57 | 2.70 | 2.50 |
Apr 15, 2024 | 2.61 | -0.27 | -9.38% | 2.88 | 2.88 | 2.58 |
Apr 12, 2024 | 2.89 | 0.00 | 0.00% | 2.89 | 2.93 | 2.78 |
Apr 11, 2024 | 2.93 | 0.02 | 0.69% | 2.91 | 3.00 | 2.90 |
Apr 10, 2024 | 2.93 | 0.03 | 1.03% | 2.90 | 2.95 | 2.85 |
Apr 9, 2024 | 2.94 | -0.08 | -2.65% | 3.02 | 3.11 | 2.92 |
Apr 8, 2024 | 3.04 | 0.04 | 1.33% | 3.00 | 3.07 | 2.93 |
Apr 5, 2024 | 3.03 | 0.13 | 4.48% | 2.90 | 3.12 | 2.89 |
Apr 4, 2024 | 2.93 | 0.06 | 2.09% | 2.87 | 2.97 | 2.80 |
Apr 3, 2024 | 2.87 | 0.04 | 1.41% | 2.83 | 2.93 | 2.83 |
Apr 2, 2024 | 2.85 | -0.05 | -1.72% | 2.90 | 2.90 | 2.78 |
Apr 1, 2024 | 2.95 | -0.02 | -0.67% | 2.97 | 3.00 | 2.93 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com